<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588989</url>
  </required_header>
  <id_info>
    <org_study_id>TGA_function</org_study_id>
    <nct_id>NCT02588989</nct_id>
  </id_info>
  <brief_title>Fibrosis, Valvular and Ventricular Function in Patients With TGA</brief_title>
  <official_title>Fibrosis, Valvular and Ventricular Function in Patients With Transposition of the Great Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to better evaluate the systemic right ventricular (RV) function in
      patients with transposition of the great arteries (TGA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with TGA frequently develop supraventricular and ventricular arrhythmia, conduction
      problems, systemic atrioventricular valve (SAVV) regurgitation, and congestive heart failure
      (CHF), all at young age. However, there is variation in time of onset of these adverse
      events. We want to evaluate ventricular and valvular function at rest, markers of RV fibrosis
      and cardiac reserve.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between fibrosis and systemic right ventricular (RV) function</measure>
    <time_frame>baseline</time_frame>
    <description>Assessment of fibrosis by cardiac magnetic resonance (CMR), assessment of RV function by echo and CMR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between systemic RV function and systemic atrioventricular valve (SAVV) regurgitation â‰¥3/4</measure>
    <time_frame>baseline</time_frame>
    <description>Assessment by echo and CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between systemic RV function and pulmonary outflow tract obstruction (POTO)</measure>
    <time_frame>baseline</time_frame>
    <description>Assessment by echo and CMR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>More pronounced deterioration of systemic RV function if fibrosis is present</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of fibrosis by CMR, assessment of RV function by echo and CMR. Paired testing to evaluate the changes between baseline values and values at 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>More pronounced deterioration of systemic RV function if POTO is absent</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment by echo and CMR. Paired testing to evaluate the changes between baseline values and values at 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>More pronounced deterioration of SAVV regurgitation severity if POTO is absent</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment by echo and CMR. Paired testing to evaluate the changes between baseline values and values at 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Composite clinical end point of new-onset sustained tachyarrhythmia (atrial/ventricular), decompensated heart failure admission, heart transplantation, or death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Transposition of Great Vessels</condition>
  <arm_group>
    <arm_group_label>transposition of the great arteries</arm_group_label>
    <description>Patients with a TGA</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Intracellular RNA collection from whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a transposition of the great arteries (TGA)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a TGA

          -  Informed consent to participate. If the patient is under the age of 18, the assent of
             the patient and the permission of the parents to participate

        Exclusion Criteria:

          -  Previous double-switch intervention

          -  Any medical contra-indication for cardiovascular magnetic resonance (CMR) imaging
             (e.g. pacemaker)

          -  The presence of exercise-induced arrhythmia, symptomatic myocardial ischemia, a
             resting systolic blood pressure &gt; 200 mm Hg and/or diastolic blood pressure &gt; 110 mm
             Hg, New York Heart Association (NYHA) class III or IV, or non-cardiac co-morbidity
             that could aggravate by exercise

          -  Additional exclusion criterion for delayed gadolinium enhancement CMR: any medical
             contra-indication for intravenous gadolinium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Budts, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Bogaert, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederik Helsen, M.D.</last_name>
    <phone>+32 16 34 22 92</phone>
    <email>frederik.helsen@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Helsen, M.D.</last_name>
      <phone>00-32-16-342292</phone>
      <email>frederik.helsen@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Situs Inversus</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

